320 related articles for article (PubMed ID: 19351745)
1. Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures.
Pacey LK; Heximer SP; Hampson DR
Mol Pharmacol; 2009 Jul; 76(1):18-24. PubMed ID: 19351745
[TBL] [Abstract][Full Text] [Related]
2. Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.
Pacey LK; Tharmalingam S; Hampson DR
J Pharmacol Exp Ther; 2011 Sep; 338(3):897-905. PubMed ID: 21636656
[TBL] [Abstract][Full Text] [Related]
3. Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes.
Musumeci SA; Calabrese G; Bonaccorso CM; D'Antoni S; Brouwer JR; Bakker CE; Elia M; Ferri R; Nelson DL; Oostra BA; Catania MV
Exp Neurol; 2007 Jan; 203(1):233-40. PubMed ID: 17007840
[TBL] [Abstract][Full Text] [Related]
4. Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse.
Pacey LK; Doss L; Cifelli C; van der Kooy D; Heximer SP; Hampson DR
Mol Cell Neurosci; 2011 Mar; 46(3):563-72. PubMed ID: 21215802
[TBL] [Abstract][Full Text] [Related]
5. Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse.
El Idrissi A; Ding XH; Scalia J; Trenkner E; Brown WT; Dobkin C
Neurosci Lett; 2005 Apr; 377(3):141-6. PubMed ID: 15755515
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome.
Romero-Zerbo Y; Decara J; el Bekay R; Sanchez-Salido L; Del Arco-Herrera I; de Fonseca FR; de Diego-Otero Y
J Pineal Res; 2009 Mar; 46(2):224-34. PubMed ID: 19141086
[TBL] [Abstract][Full Text] [Related]
7. Early postnatal plasticity in neocortex of Fmr1 knockout mice.
Desai NS; Casimiro TM; Gruber SM; Vanderklish PW
J Neurophysiol; 2006 Oct; 96(4):1734-45. PubMed ID: 16823030
[TBL] [Abstract][Full Text] [Related]
8. Early developmental alterations in GABAergic protein expression in fragile X knockout mice.
Adusei DC; Pacey LK; Chen D; Hampson DR
Neuropharmacology; 2010 Sep; 59(3):167-71. PubMed ID: 20470805
[TBL] [Abstract][Full Text] [Related]
9. Rgs4 mRNA expression is decreased in the brain of Fmr1 knockout mouse.
Tervonen T; Akerman K; Oostra BA; Castrén M
Brain Res Mol Brain Res; 2005 Jan; 133(1):162-5. PubMed ID: 15661377
[TBL] [Abstract][Full Text] [Related]
10. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice.
Gantois I; Pop AS; de Esch CE; Buijsen RA; Pooters T; Gomez-Mancilla B; Gasparini F; Oostra BA; D'Hooge R; Willemsen R
Behav Brain Res; 2013 Feb; 239():72-9. PubMed ID: 23142366
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model.
Heulens I; D'Hulst C; Van Dam D; De Deyn PP; Kooy RF
Behav Brain Res; 2012 Apr; 229(1):244-9. PubMed ID: 22285772
[TBL] [Abstract][Full Text] [Related]
12. Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome.
Wang X; Snape M; Klann E; Stone JG; Singh A; Petersen RB; Castellani RJ; Casadesus G; Smith MA; Zhu X
J Neurochem; 2012 May; 121(4):672-9. PubMed ID: 22393900
[TBL] [Abstract][Full Text] [Related]
13. A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse.
Yan QJ; Asafo-Adjei PK; Arnold HM; Brown RE; Bauchwitz RP
Genes Brain Behav; 2004 Dec; 3(6):337-59. PubMed ID: 15544577
[TBL] [Abstract][Full Text] [Related]
14. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
Yan QJ; Rammal M; Tranfaglia M; Bauchwitz RP
Neuropharmacology; 2005 Dec; 49(7):1053-66. PubMed ID: 16054174
[TBL] [Abstract][Full Text] [Related]
15. Exaggerated behavioral phenotypes in Fmr1/Fxr2 double knockout mice reveal a functional genetic interaction between Fragile X-related proteins.
Spencer CM; Serysheva E; Yuva-Paylor LA; Oostra BA; Nelson DL; Paylor R
Hum Mol Genet; 2006 Jun; 15(12):1984-94. PubMed ID: 16675531
[TBL] [Abstract][Full Text] [Related]
16. Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from Fragile X mental retardation 1-deficient mice, a pathological model for Fragile X syndrome.
el Bekay R; Romero-Zerbo Y; Decara J; Sanchez-Salido L; Del Arco-Herrera I; RodrÃguez-de Fonseca F; de Diego-Otero Y
Eur J Neurosci; 2007 Dec; 26(11):3169-80. PubMed ID: 18005058
[TBL] [Abstract][Full Text] [Related]
17. Long-term potentiation in the hippocampus of fragile X knockout mice.
Godfraind JM; Reyniers E; De Boulle K; D'Hooge R; De Deyn PP; Bakker CE; Oostra BA; Kooy RF; Willems PJ
Am J Med Genet; 1996 Aug; 64(2):246-51. PubMed ID: 8844057
[TBL] [Abstract][Full Text] [Related]
18. Increased threshold for spike-timing-dependent plasticity is caused by unreliable calcium signaling in mice lacking fragile X gene FMR1.
Meredith RM; Holmgren CD; Weidum M; Burnashev N; Mansvelder HD
Neuron; 2007 May; 54(4):627-38. PubMed ID: 17521574
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of Vlgr1 resulted in deafness and susceptibility to audiogenic seizures while the degree of hearing impairment was not correlated with seizure severity in C57BL/6- and 129-backcrossed lines of Vlgr1 knockout mice.
Yagi H; Noguchi Y; Kitamura K; Sato M
Neurosci Lett; 2009 Sep; 461(2):190-5. PubMed ID: 19539720
[TBL] [Abstract][Full Text] [Related]
20. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome.
Thomas AM; Bui N; Perkins JR; Yuva-Paylor LA; Paylor R
Psychopharmacology (Berl); 2012 Jan; 219(1):47-58. PubMed ID: 21656124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
